Protagonist Therapeutics is a biotechnology business based in the US. Protagonist Therapeutics shares (PTGX) are listed on the NASDAQ and all prices are listed in US Dollars. Protagonist Therapeutics employs 125 staff and has a trailing 12-month revenue of around $319.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $47.02 |
|---|---|
| 52-week range | $13.72 - $44.96 |
| 50-day moving average | $38.46 |
| 200-day moving average | $29.60 |
| Wall St. target price | $46.80 |
| PE ratio | 15.2574 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $2.72 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $47.02 from 2024-09-13
| 1 week (2024-09-06) | 13.30% |
|---|---|
| 1 month (2024-08-14) | 16.85% |
| 3 months (2024-06-14) | 40.82% |
| 6 months (2024-03-14) | 65.86% |
| 1 year (2023-09-14) | 161.22% |
|---|---|
| 2 years (2022-09-14) | 471.32% |
| 3 years (2021-09-14) | 4.35% |
| 5 years (2019-09-13) | 217.27% |
Valuing Protagonist Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Protagonist Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Protagonist Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, Protagonist Therapeutics shares trade at around 15x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Protagonist Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $153.2 million.
The EBITDA is a measure of a Protagonist Therapeutics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $319.1 million |
|---|---|
| Gross profit TTM | $26.6 million |
| Return on assets TTM | 20.35% |
| Return on equity TTM | 40.69% |
| Profit margin | 53.26% |
| Book value | $9.21 |
| Market Capitalization | $2.4 billion |
TTM: trailing 12 months
We're not expecting Protagonist Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Protagonist Therapeutics's shares have ranged in value from as little as $13.72 up to $44.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Protagonist Therapeutics's is 2.166. This would suggest that Protagonist Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Protagonist Therapeutics, Inc. , a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. .
Learn the basics of put options: what they are, how they work and a few examples.
Learn the basics of call options: what they are, how they work and examples.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.